Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics

Human Psychopharmacology

Volumn 27, Issue 5, 2012, Pages 521-526

  Centorrino, Franca ^a,b   Masters, Grace A ^b   Talamo, Alessandra ^a,b,c,d   Baldessarini, Ross J ^a,b   Öngür, Dost ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

antipsychotic drugs; hospitalization; metabolic syndrome; weight gain

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; HYPNOTIC AGENT; LAMOTRIGINE; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OXCARBAZEPINE; PSYCHOTROPIC AGENT; TOPIRAMATE; VALPROATE SEMISODIUM;

ADULT; AGED; AGING; ARTICLE; BODY MASS; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT DURATION;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITALIZATION; HUMANS; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; MIDDLE AGED; PSYCHOTROPIC DRUGS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84866666395     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2257     Document Type: Article

References (30)

1. Aekplakorn W, Chongsuvivatwong V, Tatsanavivat P, Suriyawongpaisal P,. 2011. Prevalence of metabolic syndrome defined by the international diabetes federation and national cholesterol education program criteria among Thai adults. Asia Pac J Public Health 23: 792-800.
2. Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, et al,. 2008. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: systematic critical reappraisal. CNS Drugs 22: 547-562.
3. American Diabetes Association (ADA), American Psychiatric Association (APA), American Association of Clinical Endocrinologists (ACE), North American Association for the Study of Obesity (NAASO). 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596-560; J Clin Psychiatry 65: 267-272.
4. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP,. 2005. Prevalence of metabolic syndrome using National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 21: 1157-1159.
5. Baldessarini RJ,. 2012. Chemotherapy in Psychiatry, 3rd edn. Springer Press: New York.
6. Bernstein JG,. 1987. Induction of obesity by psychotropic drugs. Ann NY Acad Sci 499: 203-215.
7. Bhuvaneswar C, Alpert J, Harsh V, Baldessarini RJ,. 2009. Adverse endocrine and metabolic effects of psychotropic drugs. CNS Drugs 23: 1003-1021.
8. Brewer HB, Jr., 2002. Rising to the challenge of the new NCEP ATP III guidelines: exceeding current therapeutic limitations. Am J Manag Care 8 (Suppl 2): S23-S28.
9. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher J, Baldessarini RJ,. 2004. Multiple vs. single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks vs. benefits. Am J Psychiatry 161: 700-706.
10. Centorrino F, Fogarty KV, Sani G, Salvatore P, Cimbolli P, Baldessarini RJ,. 2005. Antipsychotic drug use: McLean Hospital, 2002. Hum Psychopharmacol 20: 355-358.
11. Centorrino F, Mark TL, Talamo A, Oh K, Chang J,. 2009. Health and economic burden of metabolic co-morbidity among individuals with bipolar disorder. J Clin Psychopharmacol 29: 595-600.
12. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ,. 2010. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol 25: 179-186.
13. Cleeman JI,. 1989. National Cholesterol Education Program. Clin Lab Med 9: 7-15.
14. De Hert M, van Winkel R, Silic A, Van Eyck D, Peuskens J,. 2010. Physical health management in psychiatric settings. Eur Psychiatry 25 (Suppl 2): S22-S28.
15. Eapen V, John G,. 2011. Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go? Australas Psychiatry 19: 232-235.
16. Falissard B, Mauri M, Shaw K, et al,. 2011. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 26: 291-302.
17. Fernández-Bergés D, Cabrera de Leõn A, Sanz H, et al,. 2012. Metabolic syndrome in Spain: prevalence and coronary risk associated with harmonized definition and WHO proposal: DARIOS Study. Rev Esp Cardiol 65: 241-248.
18. Flegal KM, Carroll MD, Ogden CL, Curtin LR,. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303: 235-241.
19. Ford ES, Giles WH, Mokdad AH,. 2004. Increasing prevalence of metabolic syndrome among U.S. adults. Diabetes Care 27: 2444-2449.
20. Gardner D, Murphy A, Centorrino F, Baldessarini RJ,. 2010. Equivalent doses of antipsychotic agents: findings from an international Delphi survey. International consensus study of antipsychotic dosing. Am J Psychiatry 2010 (167): 686-693.
21. Gothefors D, Adolfsson R, Attvall S, et al,. 2010. Swedish clinical guidelines: prevention and management of metabolic risk in patients with severe psychiatric disorders. Nord J Psychiatry 64: 294-302.
22. Hennekens CH, Hennekens AR, Hollar D, Casey DE,. 2005. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150: 1115-1121.
23. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK,. 2010. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 197: 266-271.
24. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B,. 2009. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32: 1037-1042.
25. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM,. 2006. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295: 1549-1555.
26. Osborn DP, Nazareth I, King MB,. 2007. Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness: cross sectional comparative study in primary care. Soc Psychiatry Psychiatr Epidemiol 42: 787-793.
27. Ösby U, Brandt L, Correia N, Ekbom A, Sparén P,. 2001. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58: 844-850.
28. Patel JK, Buckley PF, Woolson S, et al,. 2009. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 111: 9-16.
29. Réthelyi J, Sawalhe AD,. 2011. Comorbidity of metabolic syndrome, diabetes and schizophrenia: theoretical and practical considerations (Hungarian). Orv Hetil 152: 505-511.
30. Taylor VH, McIntyre R, Remington G, Levitan RD, Stonehocker B, Sharma AM,. 2012. Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness. Can J Psychiatry 57: 5-12.